Skip to main content

23andMe is getting $50M from GSK to extend their research partnership

The DNA testing company also opted to take royalties — rather than splitting costs and profits — on the cancer drug it's developing with GSK.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.